TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from ANI Pharmaceuticals ( (ANIP) ).
On November 19, 2021, ANI Pharmaceuticals completed the acquisition of Novitium Pharma LLC and issued 25,000 shares of Series A Convertible Preferred Stock to Ampersand 2020 Limited Partnership for $25 million. By August 14, 2025, Ampersand converted 5,000 Preferred Shares into 120,580 Common Shares, and on September 26, 2025, the remaining 20,000 Preferred Shares were mandatorily converted into 482,320 Common Shares, resulting in no Preferred Shares remaining outstanding.
The most recent analyst rating on (ANIP) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
Spark’s Take on ANIP Stock
According to Spark, TipRanks’ AI Analyst, ANIP is a Neutral.
ANI Pharmaceuticals’ overall stock score is driven by strong earnings call results and technical momentum, despite valuation concerns and profitability challenges. The company’s raised guidance and product performance are significant positives, while the negative P/E ratio and overbought technical indicators pose risks.
To see Spark’s full report on ANIP stock, click here.
More about ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing, manufacturing, and marketing generic and specialty pharmaceutical products.
Average Trading Volume: 469,383
Technical Sentiment Signal: Buy
Current Market Cap: $2.06B
See more insights into ANIP stock on TipRanks’ Stock Analysis page.